contrast enhanced ultrasonography for Kidney Transplant Rejection

"Presently, there are 3 clinical trials researching the efficacy of contrast enhanced ultrasonography. Of these studies, none have reached Phase 3. While Philadelphia is a major research hub for this treatment, other sites in Pennsylvania are also running experiments on it."

"The safety of contrast enhanced ultrasonography was assessed as a 2, given the nature of this Phase 2 trial and its lack of evidence for efficacy."

"Affirmative. The clinicaltrials.gov page indicates that this experiment is still in search of patients, having been created on May 30th 2018 and last updated on the 18th of May 2021. It needs to recruit a total of 30 participants from 1 medical centre."

"At the present, this technology is being tested in three separate clinical trials across two cities and one country. The initial trial for contrast enhanced ultrasonography was conducted by GE Healthcare back in 2018, with thirty patients participating through Phase 2 drug approval. 8 research experiments have concluded since then."

"This clinical trial is recruiting 30 individuals between 18 and 75 with a history of kidney transplant at Brigham and Women's Hospital. To qualify, participants must display signs of acute or chronic renal allograft rejection as determined by the examination of histological sections from biopsies performed on said organ recipients. Additionally, stage 2 applicants are required to present normal serum creatinine values (~1 mg/dl) through medical record review."

"This research project is restricted to those aged 18-75. Additionally, there are 36 subgroups for minors and elderly participants respectively."

"Data from clinicaltrials.gov reveals that this medical trial opened on May 30th 2018 and was recently updated in 18th of May 2021, indicating it is actively recruiting patients."